Navigation Links
Thomas Jefferson University and hospitals tasked to find new radiation drugs
Date:5/4/2011

PHILADELPHIAShortly before Japan's devastating nuclear incident, researchers at Thomas Jefferson University and Hospitals (embed this link to "Hospitals" http://www.jeffersonhospital.org/) received an award to find novel drugs to treat people exposed to dangerous amounts of radiation in the wake of a nuclear terrorist attack or a nuclear accident.

Although a coincidence, the timing and the awards, given to six institutions under the National Institute of Allergy and Infectious Disease's Centers for Countermeasures Against Radiation (CMCR) program, further highlighted the pressing need for new types of drugs.

"The incident in Japan made me realize just how important and pertinent this work is," said lead researcher Ulrich Rodeck, M.D., Ph.D., a professor in the Department of Dermatology and Cutaneous Biology at Jefferson Medical College at Thomas Jefferson University, whose team received $75,000 for the pilot project that builds on six years of research. "We're taking the next step to develop better drugs to help mitigate damage from high exposure to radiation."

Dr. Rodeck, along with Adam P. Dicker, M.D, Ph.D., professor and chairman of the Department of Radiation Oncology at Jefferson, has been working on testing new drugs for radiation exposure in zebrafish since 2004. While their primary aim has been to identify compounds that could be useful in cancer treatments by protecting normal tissue against the harmful effects of radiation therapy, the research serves another purpose.

"On the one hand it could help protect the cancer patient who is treated with radiation, while on the other it may help to alleviate the kind of problems that we see right now unfolding in Japan," said Dr. Rodeck.

The work being done at Jefferson is part of a major research effort to develop medical products to diagnose, prevent and treat the short- and long-term consequences of radiation exposure that's supported by the NIH's National Institute of Allergy and Infectious Disease's CMCR program.

Only seven institutions have been tasked with this charge. Thomas Jefferson University researchers are working with Chandan Guha, M.D., Ph.D, who is the principal investigator of the new CMCR recently established at Albert Einstein Medical Center in New York, one of the institutions chosen.

Their effort builds on the use of zebrafish to study molecular mechanisms of damage by radiotherapy. Dr. Dicker's laboratory program uses this model organism in conjunction with nanotechnology drugs to identify novel radiation protectors and mitigators. This latest project will take the research into mice.

The proposed experiments focus on using small molecule agents that can be taken orally and stockpiled for quick access.

"The drugs we are working on would be of potential benefit to the workers who had to go in and repair the reactor or anyone in close proximity to a disaster of this kind," Dr. Rodeck said.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert  

Related medicine news :

1. Thomas Kipps receives ACGT Investigator Award
2. Thomas Jefferson University professor elected AAAS Fellow
3. Gala honors County Supervisor Mark Ridley-Thomas and businesswoman Anne-Merelie Murrell
4. Nationally Renowned Knee Specialist Dr. Thomas Meade Joins Coordinated Health
5. Thomas E. Heftler Migraine Research Award
6. Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15
7. Thomas E. Mower Makes Generous Donations To Primary Children's Medical Center
8. Thomas E. Mower And Karl Malone Instrumental To Success Of Sportsmen For Fish And Wildlife Organization
9. Leading Orthopaedic Surgeon and Regenerative Medical Authority Dr. Thomas A. Einhorn Advances Adult Stem Cell Therapy To Eliminate Hip Replacement Surgery
10. Thomas J. Kent Jr. FDP Capital, LLC Chairman and Former NFL Player Jack Brewer Join Forces
11. Jenesse Salutes Husband and Wife Team, Supervisor Mark Ridley-Thomas and Avis Ridley-Thomas as 2010 Silver Rose Honorees
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Thomas Jefferson University and hospitals tasked to find new radiation drugs
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... Delta ... $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired as ... was the American Cancer Society’s 2015 CEO of the Year , helped lead ...
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home show where ... see the most incredible gardens and home improvement experts that attend this amazing show. ... - 700 14th St. Denver CO, is an exciting event that Performance Mobility has ...
(Date:2/8/2016)... ... , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal ... birthday on February 10th. During this time, people can achieve better health, greater ... people from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
(Date:2/7/2016)... Dallas, Texas (PRWEB) , ... February 07, 2016 ... ... its new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and ... , MyDecision™ combines three elements to cut the cost of providing employee healthcare ...
(Date:2/6/2016)... (PRWEB) , ... February 06, 2016 , ... Shark ... to announce the launch of a new DRTV campaign with Belly Bands. , Having ... tried everything from sprays to puppy pads and find nothing works, get Belly ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016  HemaFlo Therapeutics, Inc. announced today that the United ... Number 9,119,880 covering the use of NephroFlow to treat acute ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Peterson , PhD, HemaFlo,s founder, said, "We are pleased to ... --> Dale Peterson , PhD, HemaFlo,s founder, said, ...
(Date:2/8/2016)... Feb. 8, 2016 Palatin Technologies, Inc. ... receptor-specific peptide therapeutics for the treatment of diseases ... announced today that the United States Patent and ... Allowance for U.S. Patent Application Serial Number 14/313,258 ... methods of treating female sexual dysfunction using the ...
(Date:2/5/2016)... , Feb. 5, 2016 Amgen (NASDAQ: AMGN ... Annual Global Healthcare Conference at 9:15 a.m. ET on Wednesday, ... . David W. Meline , executive vice president and ... Live audio of the presentation can be accessed from the ... A replay of the webcast will also be available on ...
Breaking Medicine Technology: